Skip to main content

Ebola

4
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
GS-5734Phase 21 trial
Active Trials
NCT02818582Completed38Est. Aug 2020
MSD
MSDIreland - Ballydine
1 program
1
V920Phase 21 trial
Active Trials
NCT03031912Completed251Est. Mar 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
V920Phase 2
Novavax
NovavaxMD - Gaithersburg
1 program
1
Base Dose EBOV GP VaccinePhase 1Vaccine1 trial
Active Trials
NCT02370589Completed230Est. Apr 2016
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
cAd3-EBO Z at 1 x 10^10 vpPHASE_11 trial
Active Trials
NCT02240875Completed91Est. Aug 2017
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
V920PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDV920
Kite PharmaGS-5734
NovavaxBase Dose EBOV GP Vaccine
Allergy TherapeuticscAd3-EBO Z at 1 x 10^10 vp

Clinical Trials (4)

Total enrollment: 610 patients across 4 trials

NCT03031912MSDV920

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Start: Aug 2017Est. completion: Mar 2023251 patients
Phase 2Completed
NCT02818582Kite PharmaGS-5734

GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Start: Jul 2016Est. completion: Aug 202038 patients
Phase 2Completed
NCT02370589NovavaxBase Dose EBOV GP Vaccine

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

Start: Feb 2015Est. completion: Apr 2016230 patients
Phase 1Completed
NCT02240875Allergy TherapeuticscAd3-EBO Z at 1 x 10^10 vp

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Start: Sep 2014Est. completion: Aug 201791 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.